GMDA Gamida Cell Ltd.

8.53
+0.14  (+2%)
Previous Close 8.39
Open 8.35
Price To Book 8.7
Market Cap 214356332
Shares 25,129,699
Volume 5,907
Short Ratio
Av. Daily Volume 16,486

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 additional data due 2H 2019.
NAM-NK
Non-Hodgkin lymphoma; Multiple myeloma
Phase 1/2 enrolment of second cohort to begin 1H 2019.
NiCord
Severe aplastic anemia
Phase 3 top-line data due 1H 2020.
NiCord
Acute myeloid leukemia

Latest News

  1. Gamida Cell to Present at the 18th Annual Needham Healthcare Conference
  2. Gamida Cell Nominates Two Healthcare Industry Veterans to Its Board of Directors
  3. Gamida Cell Sees Hammer Chart Pattern: Time to Buy?
  4. Gamida Cell Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
  5. Gamida Cell Announces Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at 2019 TCT Annual Meeting
  6. Gamida Cell Presents New Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia at 2019 TCT Annual Meeting
  7. Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells
  8. Gamida Cell to Host Conference Call and Webcast to Review Data from NAM-NK and NiCord® Programs Being Presented at 2019 TCT Annual Meeting
  9. Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at 2019 TCT Annual Meeting
  10. Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
  11. Gamida Cell Announces 2019 Goals and Provides Company Update
  12. Gamida Cell Announces Publication of Phase 1/2 Clinical Data of NiCord® in the Journal of Clinical Oncology
  13. Gamida Cell Reports Immune Reconstitution Data from Completed Phase 1/2 Clinical Study of NiCord® Presented at ASH 2018 Annual Meeting
  14. Gamida Cell to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
  15. Gamida Cell Announces New Translational Data for Nicord® to Be Presented at ASH 2018 Annual Meeting
  16. Gamida Cell Announces Pricing of Initial Public Offering
  17. StoneCo IPO Soars As Trading Begins, Yeti IPO Falls Flat
  18. Brazil's StoneCo, Yeti Holdings Headline List Of IPOs This Week